Strategies To Encourage Universal Access To Gene Therapies

18 Jul 2022

• By Shardha Millington

Inaccessible price points, development risk, and a lack of diversity in gene therapy R&D all feed into the imperfect state in which the industry's newest form of innovation exists. New approaches are needed if the patient populations that need these medicines the most can benefit.

None of the 4,442 gene therapies developed have been trialed in over 90% of African nations • Source: Shutterstock

It is no secret that the accessibility of gene therapies is a widely debated topic. Therapies continue to be brought to market at inaccessibly high price points, hindering access to the technology for the very patient population the products are designed for.

Safety concerns are creating a relatively early-stage bottleneck in the progress of gene therapies to market. However, the conversation around...